Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples.

abstract：OBJECTIVES:To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). METHODS:Three systematic literature reviews were conducted in MEDLINE and Embase to capture all relevant publications reporting 1) the epidemiology of T2D and complications in T2D and 2) th...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Alzaid A,Ladrón de Guevara P,Beillat M,Lehner Martin V,Atanasov P

更新日期：2020-07-20 00:00:00

abstract：:Skin diseases are among the most common health problems worldwide and are associated with a considerable burden. The burden of skin disease is a multidimensional concept that encompasses psychological, social and financial consequences of the skin disease on the patients, their families and on society. Chronic and inc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Basra MK,Shahrukh M

更新日期：2009-06-01 00:00:00

abstract：:Healthcare reform in any nation is an evolving process. Brought about by demographic, technological, social, cultural, economic and political factors, all healthcare systems are continually confronting issues related to cost, access and quality. This paper examines other countries' approaches to healthcare in the ongo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： O'Rourke TW,Iammarino NK

更新日期：2002-06-01 00:00:00

abstract：:A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Shepherd J,Jones J

更新日期：2007-12-01 00:00:00

abstract：:Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using conditi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrillo J,Cairns J

更新日期：2008-10-01 00:00:00

abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garg V,Gu NY,Borrego ME,Raisch DW

更新日期：2013-06-01 00:00:00

abstract：:The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Zhou XH,Ramsey S

更新日期：2003-10-01 00:00:00

abstract：:Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sankaranarayanan J,Reardon T,Olsen KM

更新日期：2014-10-01 00:00:00

abstract：:Adenosine and dipyridamole are coronary vasodilators used in nuclear imaging. The acquisition cost of adenosine is four to ten times higher than dipyridamole. Data suggest comparable sensitivity, although specificity may be lower with dipyridamole. While side effect profiles are similar, fewer patients who receive ade...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Reddy P

更新日期：2002-12-01 00:00:00

abstract：:Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Breau LM

更新日期：2003-06-01 00:00:00

abstract：AIM:To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS:This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Roger A,Fortea J,Mora S,Artés M

更新日期：2008-08-01 00:00:00

abstract：:Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Baker DA

更新日期：2005-12-01 00:00:00

abstract：:Smoking cessation is the only strategy that has shown a lasting reduction in the decline of lung function in patients with chronic obstructive pulmonary disease. This study aims to evaluate the cost-effectiveness of smoking cessation interventions in patients with chronic obstructive pulmonary disease, to assess the q...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kirsch F

更新日期：2015-04-01 00:00:00

abstract：:It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feldman SR,Pearce DJ

更新日期：2004-10-01 00:00:00

abstract：:This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

更新日期：2007-02-01 00:00:00

abstract：:The primary objective of this review is to develop a conceptual model for Crohn's disease (CD) outlining the disease burden for patients, healthcare systems and wider society, as reported in the scientific literature. A search was conducted using MEDLINE, PsycINFO, EconLit, Health Economic Evaluation Database and Cent...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gater A,Kitchen H,Heron L,Pollard C,Håkan-Bloch J,Højbjerre L,Hansen BB,Strandberg-Larsen M

更新日期：2015-01-01 00:00:00

abstract：:Ankylosing spondylitis (AS) is a complex systemic rheumatological disease which often causes severe disability and impaired quality of life (QoL). We searched the PubMed/MEDLINE electronic database for available literature on QoL and its predictors in patients with AS. Recent evidence indicates that AS patients have p...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kotsis K,Voulgari PV,Drosos AA,Carvalho AF,Hyphantis T

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

更新日期：2018-04-01 00:00:00

abstract：:Social Security Disability Insurance provides cash benefits to disabled workers and certain others under the age of 65 years. These individuals become eligible for Medicare 24 months after Social Security Disability Insurance cash benefits start. In 2001, 13.9% of Medicare's approximately 40 million beneficiaries were...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Iezzoni LI

更新日期：2006-06-01 00:00:00

abstract：OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cangelosi MJ,Ortendahl JD,Meckley LM,Bentley TG,Anene AM,Shriner KM,Fox J

更新日期：2015-04-01 00:00:00

abstract：OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

更新日期：2018-06-01 00:00:00

abstract：:At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

更新日期：2012-12-01 00:00:00

abstract：:It is a continual challenge trying to improve the quality of prescribing while concurrently trying to address increasing pharmaceutical development, utilization and expenditure. National and regional reforms and initiatives in Sweden have moderated growth in ambulatory drug expenditure to 2.7% per annum in recent year...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Godman B,Wettermark B,Hoffmann M,Andersson K,Haycox A,Gustafsson LL

更新日期：2009-02-01 00:00:00

abstract：AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Regnier SA,Alsop J,Wright J,Nixon R,Staines H,Fajnkuchen F

更新日期：2016-12-01 00:00:00

abstract：:Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gladman DD,Brown RE

更新日期：2008-04-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

更新日期：2012-06-01 00:00:00

abstract：:The pharmaceutical sector has been established as the primary cost driver in health. The scope of this paper is to explore the drivers of pharmaceutical expenditure in Cyprus by decomposing sales and assessing impact of prices, volumes and substitution effect. We used a statistical approach to decompose the growth of ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2014-04-01 00:00:00

abstract：:Up to 10% of the adult population in most countries may be affected by chronic bronchitis or chronic obstructive pulmonary disease. The course of the disease is characterized by frequent exacerbations with increased respiratory symptoms. Exacerbations are the most important cause of morbidity and mortality, and signif...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Miravitlles M

更新日期：2005-08-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Márquez-Cruz M,Díaz-Martínez JP,Soto-Molina H,De Saráchaga AJ,Cervantes-Arriaga A,Llorens-Arenas R,Rodríguez-Violante M

更新日期：2016-01-01 00:00:00

abstract：:A comprehensive literature search identified seven instruments, of which three had psychometric data available. These were the 'Sawicki instrument', the Duke Anticoagulation Satisfaction Scale (DASS) and Deep Vein Thrombosis Quality of Life (DVTQoL). Sawicki assessed five domains with acceptable internal reliability. ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wild D,Murray M,Shakespeare A,Reaney M,von Maltzahn R

更新日期：2008-06-01 00:00:00